UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 160

Sortiert nach

FOxTROT: Are We Ready to Dance?

Journal of clinical oncology, 2023-03, Vol.41 (8), p.1514-1517

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Journal of clinical oncology, 2008-11, Vol.26 (32), p.5269-5274

2008

Link zum Volltext

Verfügbarkeit prüfen

Application of new treatment strategies for mCRC: Effect of online education on clinician knowledge and confidence

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.67-67

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Journal of clinical oncology, 2021-03, Vol.39 (9), p.966-977

2021

Link zum Volltext

Verfügbarkeit prüfen

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

Journal of clinical oncology, 2021-02, Vol.39 (6), p.642-651

2021

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3568-3568

2022

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.4-4

2023

Link zum Volltext

Verfügbarkeit prüfen

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

Journal of clinical oncology, 2021-12, Vol.39 (36), p.4009-4019

2021

Link zum Volltext

Verfügbarkeit prüfen

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

Journal of clinical oncology, 2023-05, Vol.41 (14), p.2628-2637

2023

Link zum Volltext

Verfügbarkeit prüfen

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Journal of clinical oncology, 2018-05, Vol.36 (15), p.1469-1477

2018

Link zum Volltext

Verfügbarkeit prüfen

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Journal of clinical oncology, 2022-01, Vol.40 (3), p.262-271

2022

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Journal of clinical oncology, 2018-03, Vol.36 (7), p.674-681

2018

Link zum Volltext

Verfügbarkeit prüfen

The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.247-247

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4193-TPS4193

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

Journal of clinical oncology, 2020-05, Vol.38 (15), p.1702-1710

2020

Link zum Volltext

Verfügbarkeit prüfen

Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3570-3570

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS767-TPS767

2023

Link zum Volltext

Verfügbarkeit prüfen

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4134-4134

2022

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3509-3516

2005

Link zum Volltext

Verfügbarkeit prüfen

Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3515-3515

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4148-4148

2023

Link zum Volltext

Verfügbarkeit prüfen

Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3523-3523

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 160

Suche als RSS-Feed

Aktive Filter

ThemaTechnology

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(160)

Publikationsform

Artikel
(160)

Sprache

Englisch
(160)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(16)
Life Sciences & Biomedicine
(16)
Oncology
(16)
Science & Technology
(16)
Female
(14)
Male
(13)
Middle Aged
(11)
Aged
(10)
Life Sciences
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Disease-Free Survival
(6)
Adult
(5)
Fluorouracil - Therapeutic Use
(5)
Neoplasm Metastasis
(5)
Neoplasm Staging
(5)
Prognosis
(5)
Time Factors
(5)
Biological And Medical Sciences
(4)
Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

J Clin Oncol
(1)

Menü

Weitere Dienste

Einstellungen

FOxTROT: Are We Ready to Dance?

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Application of new treatment strategies for mCRC: Effect of online education on clinician knowledge and confidence

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial

Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors

Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC)

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort

Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study

Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials

Aktive Filter

Suchergebnisse filtern